Pharma companies directory 2026

Pharmaceutical Companies in Pakistan

Pakistan’s medicine market passed one trillion rupees in annual sales during 2025, and unlike most South Asian markets it is dominated by home-grown branded-generic houses rather than by multinationals or by unbranded generics.

Around 750 companies hold DRAP manufacturing or import licences, but the top fifteen account for roughly three fifths of retail value, and Getz Pharma, Sami, Searle, Abbott and GSK have traded the top positions for a decade. Most of the volume is prescription-generated but paid in cash at pharmacies, which is why field forces of several thousand medical representatives remain the main competitive weapon. Multinationals have thinned out: Sanofi and Pfizer sold their Pakistani operations to local groups in 2023–2024, while Abbott, GSK, Haleon and Novartis stayed and continue to rank among the ten largest sellers. Lahore and Karachi host most plants, formulation is almost entirely from imported APIs, and exports rose to a record $457 million in FY25 before the Afghanistan border closure cut shipments. The table below groups manufacturers, affiliates, the regulator and the largest provincial buyer so that a brand team can see who competes in each therapeutic class and through which channel.

Updated September 2026 · Drug Regulatory Authority of Pakistan (DRAP) — registered drug manufacturers and importers as of September 2026 · 21 named accounts

Request a proposal for Pakistan Browse the 21 companies

PKR 1tn+

Retail pharmaceutical sales in 2025 (about $3.8bn), IQVIA MAT December 2025

750+

Companies in the IQVIA Pakistan universe holding DRAP licences

~61%

Share of market value held by the fifteen largest companies

$457m

Pharmaceutical exports in FY25, a 34% year-on-year increase

Named accounts

Top pharmaceutical companies in Pakistan

Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Drug Regulatory Authority of Pakistan (DRAP) — registered drug manufacturers and importers (as of 2026-09-03).

#	Company	HQ	Type	Therapeutic focus	Notes
01	Getz Pharma	Karachi	Local	Cardiometabolic, anti-infectives, gastroenterology, CNS	Privately held company that has held the top retail position for several years and runs one of the largest field forces in the country.
02	The Searle Company	Karachi	Local	Gastroenterology, cardiology, paediatric antibiotics	PSX-listed member of the IBL group with brands such as Nuberol and Gravinate; also sells through its sister distributor IBL Operations.
03	Sami Pharmaceuticals	Karachi	Local	Antibiotics, urology, ophthalmics, dermatology	Family-owned manufacturer consistently in the top three by value, with strong hospital anti-infective franchises and a growing export book.
04	GSK Pakistan	Karachi	MNC	Antibiotics, respiratory, vaccines, dermatology	PSX-listed affiliate manufacturing at Karachi sites; Augmentin and Calpol remain among the country’s largest brands by revenue.
05	Abbott Laboratories (Pakistan)	Karachi	MNC	Established pharmaceuticals, paediatric nutrition, diagnostics	Listed affiliate whose Brufen, Duphaston and nutrition lines give it one of the broadest pharmacy footprints among multinationals.
06	Haleon Pakistan	Karachi	MNC	OTC analgesics, oral care, vitamins	Consumer-health company spun out of GSK, owning Panadol, the single largest pharmacy brand in Pakistan by value.
07	Novartis Pharma (Pakistan)	Karachi	MNC	Cardiology, oncology, immunology, ophthalmology	Innovator affiliate with a Jamshoro manufacturing legacy; now concentrates on specialty launches and patient-access programmes.
08	Hilton Pharma	Karachi	Local	Cardiology, diabetes, anti-infectives, licensed brands	Manufactures its own portfolio and in-licenses products from foreign originators, making it a frequent partner for companies without an affiliate.
09	Ferozsons Laboratories	Lahore	Local	Hepatology, oncology, gastroenterology, biologics via BF Biosciences	PSX-listed firm known for licensed hepatitis C antivirals and for BF Biosciences, its joint venture producing interferons and biosimilars.
10	Highnoon Laboratories	Lahore	Local	Cardiology, diabetes, GI, respiratory	Listed Lahore manufacturer with seven brands above one billion rupees and export awards in 2024 and 2025 for its African and Asian shipments.
11	CCL Pharmaceuticals	Lahore	Local	Cardiology, CNS, gastroenterology, injectables	Privately held Lahore company with a large primary-care field force and a growing presence in Central Asian export markets.
12	Martin Dow	Karachi	Local	Cardiology, CNS, vitamins, licensed innovator brands	Acquired Roche’s Pakistani plant and later Merck KGaA’s local business, so its portfolio mixes own generics with ex-innovator brands.
13	AGP Limited	Karachi	Local	Cardiometabolic, respiratory, licensed and acquired brands	PSX-listed company built through acquisitions, including the Pakistan rights to several multinational portfolios and a Sandoz distribution agreement.
14	Bosch Pharmaceuticals	Karachi	Local	Anti-infectives, gastroenterology, cardiology	Mid-sized manufacturer that has climbed the retail rankings through aggressive primary-care promotion and rapid generic launches.
15	PharmEvo	Karachi	Local	Cardiology, diabetes, urology, gastroenterology	Karachi company with a reputation for medical education programmes and export registrations across Africa and Southeast Asia.
16	OBS Pakistan	Karachi	Local	Ex-AstraZeneca and MSD brands, cardiology, anti-infectives	Took over the Pakistani operations of AstraZeneca and later parts of MSD’s portfolio, illustrating how local groups absorb departing multinationals.
17	Macter International	Karachi	Local	Anti-infectives, cardiology, dermatology, biosimilars	Listed manufacturer with a dedicated biosimilar unit and one of the older EU-audited facilities in Karachi.
18	Atco Laboratories	Karachi	Local	Anti-infectives, gynaecology, nutrition, dermatology	Family-run company whose antibiotic and gynaecology franchises are widely prescribed in secondary cities of Sindh and Punjab.
19	Drug Regulatory Authority of Pakistan (DRAP)	Islamabad	Government	Registration, GMP licensing, pricing and pharmacovigilance	Federal regulator whose pricing decisions and registration timelines determine launch sequencing for every company on this list.
20	Punjab Specialized Healthcare & Medical Education Department	Lahore	Government	Tenders for teaching hospitals and tertiary institutes	Largest single provincial buyer of hospital medicines, procuring for Mayo, Jinnah, Services and other teaching hospitals in Punjab.
21	Muller & Phipps Pakistan	Karachi	Distributor	National distribution for multinational and local principals	Distribution house that physically delivers many of the brands above to pharmacies and hospitals; a shared dependency across competitors.

Primary research

These are the pharmaceutical companies accounts we study in Pakistan

Need account-level or SKU-level data for a brand in Pakistan? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

Planning research in Pakistan?

Primary research, market access & HEOR. Proposals within 48 hours.

BioNixus research services

How the market is structured

How pharmaceutical companies reach patients in Pakistan

Every product sold in Pakistan needs a DRAP registration and, for imports, a locally licensed importer who becomes the marketing authorisation holder; multinationals use their own affiliate while smaller foreign firms appoint a Pakistani partner such as AGP, OBS or Hilton to hold the file. DRAP also sets maximum retail prices, with essential medicines under a tighter formula than the non-essential list that was deregulated in 2024, so launch timing is planned around pricing decisions. Once registered, a company hands physical distribution to one or two national distributors, most often Muller & Phipps, IBL Operations, Premier Agencies or Ali Gohar, which carry stock to some 50,000 pharmacies and medical stores and to private hospitals on credit. Demand creation stays with the manufacturer: sales representatives call on general practitioners, consultants and hospital pharmacists, and prescription share is tracked through IQVIA panel data and pharmacy audits. Public procurement is provincial rather than national, so Punjab, Sindh, Khyber Pakhtunkhwa and Balochistan each tender for their hospital networks and basic health units, and the Sehat Sahulat insurance scheme routes inpatient volume to empanelled private hospitals in KP and parts of Punjab. Organised pharmacy chains such as Servaid, D.Watson and Dvago and online platforms are still a small slice of outlets but negotiate listings directly, especially for OTC and nutrition lines.

Local

Karachi and Lahore-based branded-generic manufacturers that dominate prescription value, run large medical-representative teams and increasingly in-license or acquire multinational brands.

Getz Pharma
The Searle Company
Sami Pharmaceuticals
Hilton Pharma
Ferozsons Laboratories
Highnoon Laboratories
CCL Pharmaceuticals
Martin Dow
AGP Limited
Bosch Pharmaceuticals
PharmEvo
OBS Pakistan
Macter International
Atco Laboratories

Multinational

The remaining innovator and consumer-health affiliates, several of them PSX-listed, that manufacture locally and hold the largest single pharmacy brands in analgesics, antibiotics and nutrition.

GSK Pakistan
Abbott Laboratories (Pakistan)
Haleon Pakistan
Novartis Pharma (Pakistan)

Regional

Gulf and South Asian groups that enter through licensing agreements with Pakistani manufacturers or through DRAP-registered importers rather than with their own affiliates.

Distributors & importers

The national distributors that carry stock on credit to tens of thousands of outlets, plus the federal regulator and provincial health departments that set prices and award public tenders.

Drug Regulatory Authority of Pakistan (DRAP)
Punjab Specialized Healthcare & Medical Education Department
Muller & Phipps Pakistan

What is moving

What is moving the pharmaceutical market in Pakistan

Price deregulation of non-essential medicines

DRAP’s 2024 decision to free prices of products outside the essential list lifted industry margins above 40% and triggered a wave of relaunches, so companies are re-evaluating which brands to promote and which to harvest.

Multinational exits and local consolidation

Sale of the Pfizer and Sanofi affiliates to Pakistani groups, following the earlier AstraZeneca, Roche and Merck transfers, keeps moving established brands into local hands and reshuffling field-force coverage across therapy areas.

Export drive and regulatory upgrades

Record shipments to Africa, Central Asia and the Philippines, supported by PharmEx Pakistan and WHO-GMP upgrades, are pushing Highnoon, Getz, PharmEvo and CCL to invest in plants that also raise domestic quality benchmarks.

Chronic disease and insurance-backed hospital demand

Diabetes prevalence above 30% in adults, rising hypertension and Sehat Sahulat coverage in KP and Punjab expand cardiometabolic prescribing and institutional purchasing, favouring companies with both primary-care and hospital teams.

BioNixus fieldwork

How BioNixus studies pharmaceutical companies in Pakistan

The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Pakistan:

Brand-perception and detailing-quality interviews with 60–120 general practitioners, cardiologists and diabetologists across five cities, benchmarking local branded generics against multinational originals.
Molecule-level brand share estimation from pharmacy purchase-record audits in Karachi, Lahore and Rawalpindi for cardiometabolic, antibiotic and gastro baskets.
Provincial tender landscaping covering Punjab, Sindh and KP awards, bidder lists and price points for hospital injectables and oncology.
Hospital pharmacist and purchase-committee interviews on formulary inclusion, credit terms and distributor service for private hospital groups in Karachi and Lahore.

Questions

Frequently Asked Questions

Which pharmaceutical companies sell the most in Pakistan?

Getz Pharma, Sami, Abbott, GSK and Searle usually occupy the top five positions in IQVIA retail audits, followed by Haleon, Hilton, Highnoon, Martin Dow and Novartis. Positions shift year to year, and local companies now hold most of the top twenty.

Are multinationals leaving Pakistan?

Several have sold their affiliates to local groups because of currency depreciation and price controls, including Pfizer, Sanofi, AstraZeneca and Merck KGaA. Abbott, GSK, Haleon and Novartis remain with manufacturing or commercial operations in Karachi.

How are medicine prices set in Pakistan?

DRAP fixes maximum retail prices for essential medicines under the Drug Pricing Policy, with annual adjustments linked to inflation. Prices of non-essential medicines were deregulated in 2024, which is why margins and launch activity rose sharply in 2025.

Who buys medicines for public hospitals in Pakistan?

Health is a provincial responsibility, so Punjab, Sindh, Khyber Pakhtunkhwa and Balochistan run their own tenders, with Punjab’s specialised healthcare and primary healthcare departments the largest buyers. Federal institutions and the armed forces procure separately.

How does BioNixus research pharmaceutical companies in Pakistan?

By interviewing prescribers, hospital pharmacists and pharmacy owners in Karachi, Lahore, Islamabad, Peshawar and secondary cities on brand perception and representative quality, auditing pharmacy purchase records to estimate brand share by molecule, and mapping provincial tender awards.

Is this a ranking of Pakistani pharmaceutical companies?

It is not. The list groups manufacturers, affiliates and public bodies that appear repeatedly in BioNixus Pakistan projects and on DRAP records; sequence in the table does not reflect turnover or market share.

Sources

Data sources & methodology

This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Pakistan. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

Primary register: Drug Regulatory Authority of Pakistan (DRAP) — registered drug manufacturers and importers, consulted 2026-09-03. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Pakistan, not size.

IQVIA Pakistan retail audit, MAT December 2025, as cited in Highnoon Laboratories corporate briefing, 2026
PACRA pharmaceutical sector research and State Bank of Pakistan export data, FY25–FY26
Pakistan Stock Exchange annual reports for Searle, GSK Pakistan, Abbott Pakistan, Ferozsons, Highnoon, AGP and Macter, 2024–2025
BioNixus Pakistan prescriber, pharmacy and hospital fieldwork, 2023–2026

BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

48-hour proposal

Need brand and competitor data in Pakistan?

Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

Planning research in Pakistan?

Primary research, market access & HEOR. Proposals within 48 hours.

Pharmaceutical Companies in Pakistan

Top pharmaceutical companies in Pakistan

These are the pharmaceutical companies accounts we study in Pakistan

Planning research in Pakistan?

How pharmaceutical companies reach patients in Pakistan

Local

Multinational

Regional

Distributors & importers

What is moving the pharmaceutical market in Pakistan

Price deregulation of non-essential medicines

Multinational exits and local consolidation

Export drive and regulatory upgrades

Chronic disease and insurance-backed hospital demand

How BioNixus studies pharmaceutical companies in Pakistan

Related research and directories

More company directories for Pakistan

Frequently Asked Questions

Data sources & methodology

Need brand and competitor data in Pakistan?

Planning research in Pakistan?